Glycosylation decreases aggregation and immunogenicity of adalimumab Fab secreted from Pichia pastoris

Hitomi Nakamura, Masato Kiyoshi, Makoto Anraku, Noritaka Hashii, Naoko Oda-Ueda, Tadashi Ueda, Takatoshi Ohkuri

研究成果: Contribution to journalArticle査読

1 被引用数 (Scopus)


Glycoengineering of therapeutic proteins has been applied to improve the clinical efficacy of several therapeutics. Here, we examined the effect of glycosylation on the properties of the Fab of the therapeutic antibody, adalimumab. An N-glycosylation site was introduced at position 178 of the H chain constant region of adalimumab Fab through site-directed mutagenesis (H:L178N Fab), and the H:L178N Fab was produced in Pichia pastoris. Expressed mutant Fab contained long and short glycan chains (L-glyco Fab and S-glyco Fab, respectively). Under the condition of aggregation of Fab upon pH shift-induced stress, both of L-glyco Fab and S-glyco Fab were less prone to aggregation, with L-glyco Fab suppressing aggregation more effectively than the S-glyco Fab. Moreover, the comparison of the antigenicity of glycosylated and wild-type Fabs in mice revealed that glycosylation resulted in the suppression of antigenicity. Analysis of the pharmacokinetic behaviour of the Fab, L-glyco Fab and S-glyco Fab indicated that the half-lives of glycosylated Fabs in the rats were shorter than that of wild-type Fab, with L-glyco Fab having a shorter half-life than S-glyco Fab. Thus, we demonstrated that the glycan chain influences Fab aggregation and immunogenicity, and glycosylation reduces the elimination half-life in vivo.

ジャーナルJournal of biochemistry
出版ステータス出版済み - 4 29 2021

All Science Journal Classification (ASJC) codes

  • 生化学
  • 分子生物学


「Glycosylation decreases aggregation and immunogenicity of adalimumab Fab secreted from Pichia pastoris」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。